This study, based on real-world data, supports the feasibility and favorable outcome of pembrolizumab monotherapy as a front-line treatment for high-level PD-L1 (TPS ≥ 50%) NSCLC diagnosed with BM, especially in association with local therapy. The gene discussed is CD274; the disease is non-small cell lung carcinoma.